King Pharmaceuticals KG International — Incurred loss and LAE, net of reinsurance

Other product segments

Similar metrics at other companies

HGInternational - Casualty — Incurred Losses and Allocated Loss Adjustment Expenses, Net of Reinsurance

$889.32M+348%

HGInternational - Property — Incurred Losses and Allocated Loss Adjustment Expenses, Net of Reinsurance

$633.55M+344%

HGInternational - Specialty — Incurred Losses and Allocated Loss Adjustment Expenses, Net of Reinsurance

$1.2B+444%

HGTotal International — Loss Ratio

56.3%-4.3pp

FRHCLife Insurance — Incurred losses and LAE, net of reinsurance for the years ended March 31

$4.91M-80.4%

CNAInternational — Policyholder Benefits and Claims Incurred, Net

$204M+6.3%

Questions, answered.

What is King Pharmaceuticals's international — incurred loss and LAE, net of reinsurance?

King Pharmaceuticals (KG) reported international — incurred loss and LAE, net of reinsurance of 56,319,200,000% in Q4 2025.

How has King Pharmaceuticals's international — incurred loss and LAE, net of reinsurance changed year-over-year?

King Pharmaceuticals's international — incurred loss and LAE, net of reinsurance increased by 548.7% year-over-year, from 8,682,100,000% to 56,319,200,000%.

What does international — incurred loss and LAE, net of reinsurance mean?

This represents the total cost of claims and associated loss adjustment expenses (LAE) incurred by the international segment, net of any recoveries from reinsurance partners. It serves as a primary indicator of underwriting profitability and the effectiveness of risk selection within the international insurance product line. A lower ratio relative to premiums earned suggests superior underwriting performance.